We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year.
- Authors
Kanokudom, Sitthichai; Chansaenroj, Jira; Assawakosri, Suvichada; Suntronwong, Nungruthai; Yorsaeng, Ritthideach; Wongsrisang, Lakkhana; Aeemjinda, Ratchadawan; Vichaiwattana, Preeyaporn; Klinfueng, Sirapa; Thatsanathorn, Thaksaporn; Honsawek, Sittisak; Poovorawan, Yong
- Abstract
This study investigated the impact of hybrid immunity on antibody responses in the participants who received two to seven doses of the COVID-19 vaccine. The study was conducted between April and June 2023. Out of 771 serum samples analyzed, 71.7% exhibited hybrid immunity (positive for total anti-N Ig), while 28.3% showed vaccine-induced immunity (negative for total anti-N Ig). Participants were categorized based on the number of vaccine doses: 2, 3, 4, and ≥5. The findings highlight a trend where a higher number of vaccine doses received was associated with a lower infection rate. There was no significant difference in total RBD Ig levels between those who received 3, 4, or ≥5 doses in both the hybrid immunity and vaccination alone groups across all observed durations as follows: <6 months, 6 to <9 months, 9 to <12 months, and ≥12 months. Hybrid immunity consistently maintained higher total RBD Ig levels and durability compared to vaccination alone, with estimated half-lives (T1/2) of 189.5 days versus 106.8 days for vaccine alone. This investigation underscored the potential benefit of hybrid immunity and raised questions about the optimal strategies for further vaccine dosing.
- Subjects
IMMUNITY; SARS-CoV-2; ANTIBODY formation; COVID-19 vaccines; IMMUNOGLOBULINS
- Publication
Vaccines, 2023, Vol 11, Issue 11, p1693
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines11111693